VX-11e

• Description:

  VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with Ki < 2 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  ERK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/VX-11e.html

• Purity:

  98.94

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  FC1=CC(Cl)=C(NC2=NC(C3=CNC(C(N[C@H](CO)C4=CC=CC(Cl)=C4)=O)=C3)=C(C)C=N2)C=C1

• Molecular Formula:

  C24H20Cl2FN5O2

• Molecular Weight:

  500.35

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Aronov, Alex M., et al. Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control. Journal of Medicinal Chemistry (2009), 52 (20), 6362-6368.|[2]Krepler C, et al. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 2016 Apr 1;22 (7) :1592-602.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  ERK2

• CAS Number:

  [896720-20-0]